Fasciculation and elongation protein zeta-1 (FEZ1) expression in reactive astrocytes in a rat model of Parkinson's disease

Neuropathology and Applied Neurobiology

Volumn 40, Issue 2, 2014, Pages 164-176

  Sun, Y Y ^a   Zhang, Y ^a,c   Sun, X P ^a   Liu, T Y ^a   Liu, Z H ^a   Chen, G ^b   Xia, C L ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c JIANGSU UNIVERSITY   (China)

Author keywords

Astrocytes; Dopaminergic neurone; Fasciculation and elongation protein zeta 1; Parkinson's disease; Rat; Tyrosine hydroxylase

Indexed keywords

FASCICULATION AND ELONGATION PROTEIN ZETA 1; MESSENGER RNA; OXIDOPAMINE; PROTEIN; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GLIA CELL; IMMUNOHISTOCHEMISTRY; MALE; MEDIAL FOREBRAIN BUNDLE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ASTROCYTES; DOPAMINERGIC NEURONE; FASCICULATION AND ELONGATION PROTEIN ZETA-1; PARKINSON'S DISEASE; RAT; TYROSINE HYDROXYLASE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ASTROCYTES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; MALE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84892662747     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12077     Document Type: Article

References (44)

1. Heisters D. Focus on Parkinson's: causes, treatment and support. Br J Community Nurs 2011; 16: 182-183
2. Arenas E. Towards stem cell replacement therapies for Parkinson's disease. Biochem Biophys Res Commun 2010; 396: 152-156
3. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994; 59: 401-405
4. von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 2004; 73: 151-177
5. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005; 28: 57-87
6. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909
7. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991; 41: 202-205
8. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B. Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol Disord Drug Targets 2010; 9: 349-372
9. Zhang ZJ, Zhao LX, Cao DL, Zhang X, Gao YJ, Xia C. Curcumin inhibits LPS-induced CCL2 expression via JNK pathway in C6 rat astrocytoma cells. Cell Mol Neurobiol 2012; 32: 1003-1010
10. Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002; 82: 981-1011
11. Abbadie C. Chemokines, chemokine receptors and pain. Trends Immunol 2005; 26: 529-534
12. Inoue K. The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol Ther 2006; 109: 210-226
13. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009; 10: 23-36
14. Benarroch EE. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin Proc 2005; 80: 1326-1338
15. Giaume C, Koulakoff A, Roux L, Holcman D, Rouach N. Astroglial networks: a step further in neuroglial and gliovascular interactions. Nat Rev Neurosci 2010; 11: 87-99
16. Fellin T. Communication between neurons and astrocytes: relevance to the modulation of synaptic and network activity. J Neurochem 2009; 108: 533-544
17. Alexander JK, Fuss B, Colello RJ. Electric field-induced astrocyte alignment directs neurite outgrowth. Neuron Glia Biol 2006; 2: 93-103
18. Mena MA, de Bernardo S, Casarejos MJ, Canals S, Martín ER. The role of astroglia on the survival of dopamine neurons. Mol Neurobiol 2002; 25: 245-263
19. Dervan AG, Meshul CK, Beales M, McBean GJ, Moore C, Totterdell S, Snyder AK, Meredith GE. Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. Exp Neurol 2004; 190: 145-156
20. Bloom L, Horvitz HR. The Caenorhabditis elegans gene unc-76 and its human homologs define a new gene family involved in axonal outgrowth and fasciculation. Proc Natl Acad Sci U S A 1997; 94: 3414-3419
21. Kuroda S, Nakagawa N, Tokunaga C, Tatematsu K, Tanizawa K. Mammalian homologue of the Caenorhabditis elegans UNC-76 protein involved in axonal outgrowth is a protein kinase C zeta-interacting protein. J Cell Biol 1999; 144: 403-411
22. Suzuki T, Okada Y, Semba S, Orba Y, Yamanouchi S, Endo S, Tanaka S, Fujita T, Kuroda S, Nagashima K, Sawa H. Identification of FEZ1 as a protein that interacts with JC virus agnoprotein and microtubules: role of agnoprotein-induced dissociation of FEZ1 from microtubules in viral propagation. J Biol Chem 2005; 280: 24948-24956
23. Naghavi MH, Hatziioannou T, Gao G, Goff SP. Overexpression of fasciculation and elongation protein zeta-1 (FEZ1) induces a post-entry block to retroviruses in cultured cells. Genes Dev 2005; 19: 1105-1115
24. Ikuta J, Maturana A, Fujita T, Okajima T, Tatematsu K, Tanizawa K, Kuroda S. Fasciculation and elongation protein zeta-1 (FEZ1) participates in the polarization of hippocampal neuron by controlling the mitochondrial motility. Biochem Biophys Res Commun 2007; 353: 127-132
25. Fujita T, Maturana AD, Ikuta J, Hamada J, Walchli S, Suzuki T, Sawa H, Wooten MW, Okajima T, Tatematsu K, Tanizawa K, Kuroda S. Axonal guidance protein FEZ1 associates with tubulin and kinesin motor protein to transport mitochondria in neurites of NGF-stimulated PC12 cells. Biochem Biophys Res Commun 2007; 361: 605-610
26. Fujita T, Ikuta J, Hamada J, Okajima T, Tatematsu K, Tanizawa K, Kuroda S. Identification of a tissue-non-specific homologue of axonal fasciculation and elongation protein zeta-1. Biochem Biophys Res Commun 2004; 313: 738-744
27. Honda A, Miyoshi K, Baba K, Taniguchi M, Koyama Y, Kuroda S, Katayama T, Tohyama M. Expression of fasciculation and elongation protein zeta-1 (FEZ1) in the developing rat brain. Brain Res Mol Brain Res 2004; 122: 89-92
28. He J, Liu J, Zhang Z, Sun M, Zhu T, Xia C. Expression of fasciculation and elongation protein zeta-1 (FEZ1) in cultured rat neonatal astrocytes. Mol Cell Biochem 2009; 325: 159-167
29. Yu Z, Ono C, Kim HB, Komatsu H, Tanabe Y, Sakae N, Nakayama KI, Matsuoka H, Sora I, Bunney WE, Tomita H. Four mood stabilizers commonly induce FEZ1 expression in human astrocytes. Bipolar Disord 2011; 13: 486-499
30. Jeong JY, Einhorn Z, Mercurio S, Lee S, Lau B, Mione M, Wilson SW, Guo S. Neurogenin1 is a determinant of zebrafish basal forebrain dopaminergic neurons and is regulated by the conserved zinc finger protein Tof/Fezl. Proc Natl Acad Sci U S A 2006; 103: 5143-5148
31. Jeong JY, Einhorn Z, Mathur P, Chen L, Lee S, Kawakami K, Guo S. Patterning the zebrafish diencephalon by the conserved zinc-finger protein Fezl. Development 2007; 134: 127-136
32. Sakae N, Yamasaki N, Kitaichi K, Fukuda T, Yamada M, Yoshikawa H, Hiranita T, Tatsumi Y, Kira J, Yamamoto T, Miyakawa T, Nakayama KI. Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants. Hum Mol Genet 2008; 17: 3191-3203
33. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 6th edn. San Diego, CA: Academic Press, 2007
34. Riddibough G. Homing in on the homeobox. Nature 1992; 357: 643-645
35. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996; 67: 443-462
36. Miller RL, James-Kracke M, Sun GY, Sun AY. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 2009; 34: 55-65
37. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005; 2: 484-494
38. Uversky VN. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 2004; 318: 225-241
39. Tolwani RJ, Jakowec MW, Petzinger GM, Green S, Waggie K. Experimental models of Parkinson's disease: insights from many models. Lab Anim Sci 1999; 49: 363-371
40. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996; 50: 275-331
41. McGinnis W, Levine MS, Hafen E, Kuroiwa A, Gehring WJ. A conserved DNA sequence in homoeotic genes of the Drosophila Antennapedia and bithorax complexes. Nature 1984; 308: 428-433
42. Shapiro RM, Glick SD, Camarota NA. A two-population model of rat rotational behavior: effects of unilateral nigrostriatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation. Brain Res 1987; 426: 323-331
43. Zetterstroem T, Brundin P, Gage FH, Sharp T, Isacson O, Dunnett SB, Ungerstedt U, Björklund A. In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis. Brain Res 1986; 362: 344-349
44. Allen NJ, Barres BA. Glia-more than just brain glue. Nature 2009; 457: 675-677